Ipca Laboratories delivered robust financial performance in the December quarter, with net profit rising 31.5% year-on-year to ₹326.3 crore in Q3 FY26, compared with ₹248 crore in the corresponding period last year. According to reports from CNBC TV18, the pharmaceutical company's profit growth significantly outpaced revenue expansion during the quarter ended December 31, 2025.
Revenue for the quarter increased 6.6% to ₹2,392.5 crore from ₹2,245.4 crore a year earlier, as reported by CNBC TV18. The revenue growth was supported by strong performance across both domestic and international markets, with the company maintaining its focus on export-oriented business operations. Latest data from Capital Market - Live shows the company's total revenue reached ₹2,392.50 crore in Q3 FY26 compared to ₹2,245.37 crore in the previous year, demonstrating consistent growth momentum.
Operating performance showed significant improvement during the quarter. EBITDA grew 15.2% year-on-year to ₹533.7 crore from ₹463.4 crore, while EBITDA margin expanded to 22.3% from 20.6% in the year-ago period, as reported by CNBC TV18. This margin expansion reflects improved operational efficiencies and favorable business mix during the quarter.
On the segmental front, Indian formulations income rose 12% to ₹984 crore, demonstrating steady traction in the domestic market, according to CNBC TV18. Export income also grew 13% to ₹770.49 crore, supporting overall revenue growth during the quarter and contributing to the company's export-focused business model. The company's export formulation business experienced significant growth of 17% in Q3, as reported by Capital Market - Live, highlighting the strong international market performance.
Following the earnings announcement on Friday, February 13, shares of Ipca Laboratories were trading at ₹1,487.95 apiece, up ₹12.55 or 0.85% on the NSE as of 01:48 PM, as reported by CNBC TV18. The positive market response reflects investor confidence in the company's strong quarterly performance and improved operational metrics. Recent trading data shows the stock quoting at ₹1,515.30 with a market capitalization of ₹37,388.39 crore, indicating continued investor interest in the pharmaceutical company's growth trajectory.
